---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-027504"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T06:04:54.958590+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zura Bio FY 2024 net loss $45.4M ($0.60/sh); cash $176.5M, runway to 2027

## Summary
- Cash and cash equivalents $176.5M as of Dec 31, 2024, up from $99.8M at year-end 2023; sufficient to fund operations through 2027.
- Net loss improved to $45.4M ($0.60 per share) from $69.2M ($2.09 per share) in 2023.
- Initiated Phase 2 TibuSURE trial for tibulizumab in systemic sclerosis (SSc) in Dec 2024; Phase 2 HS trial planned for Q2 2025.
- Completed $112.5M private placement in April 2024; also executed warrant exchange and established ATM program in 2024.
- Robert Lisicki appointed CEO in April 2024; Kiran Nistala joined as CMO in Jan 2024; Scientific Advisory Board established June 2024.

## SEC filing metadata
- accession: 0001104659-25-027504
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465925027504/0001104659-25-027504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465925027504/tm2510115d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-027504
- JSON: https://secwatch.observer/filing/0001104659-25-027504.json
- Plain text: https://secwatch.observer/filing/0001104659-25-027504.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.